Records calculated body surface area used for BSA-based chemotherapy dosing.

Records a CTCAE-graded adverse event observation linked to a chemotherapy administration.

Records the clinical suspicion of cancer prior to confirmed diagnosis, capturing suspicion level and reasons.

Electronic prescription for a chemotherapy agent, including dose, route, cycle timing and BSA-based dosing details.

Records ECOG performance status at a given encounter to support treatment decisions.

Records histopathological morphology findings for an oncology diagnosis, including tissue type and biopsy method.

Captures an oncology adverse event including CTCAE grade, attribution and actions taken.

Represents a structured oncology treatment care plan (chemotherapy, radiotherapy or multimodal) for a patient under the National Cancer Control Programme.

The multidisciplinary oncology care team responsible for the patient's cancer management.

Insurance claim for oncology treatment submitted to SHA, including staging, treatment setting and session details.

Response from SHA to an oncology prior authorization or claim, including sessions covered and cycle boundaries.

Request to verify patient insurance coverage eligibility for oncology treatment.

Represents a confirmed or suspected cancer diagnosis using ICD-11 post-coordinated coding for the NCCP.

Diagnostic report for oncology investigations including pathology and radiology.

Electronic request for diagnostic investigations (lab, imaging, pathology) in the oncology workflow.

An oncology clinical encounter (treatment session, diagnostic visit, consultation) linked to the oncology episode of care.

Represents the full episode of cancer care for a patient, linking diagnosis, care team and managing organization.

Records the actual administration of a chemotherapy agent during a treatment session.

Template for an oncology treatment regimen (e.g., AC-T, FOLFOX) used to instantiate care plans.

Records referral of a patient to an oncology specialist or cancer centre.

Groups all medication requests for a single chemotherapy cycle session.

Documents prior bone marrow transplant relevant to the patient's haematological cancer history.

Documents prior radiotherapy treatment relevant to the patient's cancer history.

Documents prior surgical procedures relevant to the patient's cancer history.

Documents prior systemic therapy (chemotherapy, immunotherapy, hormonal) relevant to the patient's cancer history.

Records baseline tumour measurements at the start of therapy for RECIST response assessment.

Records presence or absence of new lesions at a RECIST assessment timepoint.

Records qualitative assessment of RECIST non-target lesions.

Records the overall RECIST tumour response assessment (CR, PR, SD, PD) at a given timepoint.

Records measurement of a single RECIST target lesion at a specific timepoint.

Radiotherapy-specific care plan capturing fractions, dose per fraction, technique and target volume.

Summarises cumulative dose, dose per fraction and total fractions for a radiotherapy course.

Template radiotherapy protocol defining total fractions, dose per fraction and technique.

Prescription and referral for radiotherapy treatment, including intent, technique and target volume.

Records a single radiotherapy fraction delivery event, including dose, beam type and machine.

Records TNM staging components (T, N, M) and overall stage for an oncology diagnosis.

Cycle number from which this medication applies

Cycle number up to which this medication applies

Type of bone marrow transplant procedure

Indicates if dose is calculated based on body surface area

Formula used to calculate body surface area

Action taken in response to the adverse event

Causality attribution of adverse event to treatment

CTCAE severity grade (1-5)

Level of clinical suspicion for cancer

Overall cancer stage for claims

Reference to the medication administration that caused the adverse event

Clinical category of the medication in the regimen

Details of coinsurance arrangement

Comorbidity information relevant to the claim

Cost of a single treatment session

Last day of cycle on which medication is given

First day of cycle on which medication is given

Length of each treatment cycle in days

Treatment cycle number

Current status of the oncology diagnosis

Dose per unit (e.g., mg/m2 or mg/kg)

Last cycle covered by authorization

Indicates whether coinsurance applies

Sites of metastatic disease

Reference to a parent prior authorization claim

Number of planned treatment cycles

Full post-coordinated ICD-11 code string

Outcome of prior treatment before referral

OCM protocol markers for diagnostic ordering

Unique identifier for a RECIST target lesion

RECIST assessment timepoint (baseline, on-treatment, etc.)

Type of beam used in radiotherapy

Cumulative radiation dose delivered to date

Dose delivered per radiotherapy fraction (in Gy)

Sequential fraction number in the radiotherapy course

Intent of radiotherapy treatment

Target volume definition for radiotherapy

Total number of radiotherapy fractions planned

Identifier of the radiotherapy treatment machine used

Technique used for radiotherapy delivery

Reason for clinical cancer suspicion

Source of the oncology referral

Code identifying the treatment regimen from Livia

Reference to the oncology care plan (regimen)

Expected date of the treatment session

Unique session identifier from source system

Sequential session number within a cycle

Number of sessions covered by insurer in claim response

Number of sessions per treatment cycle

Total number of sessions required for the course

Number of sessions already used

First cycle covered by authorization

Flag indicating patient is eligible for treatment

The intended treatment goal (curative, palliative, etc.)

Clinical setting where treatment is administered

Adverse event category codes for oncology adverse event reporting

Types of bone marrow or haematopoietic stem cell transplant.

Body surface area calculation formula codes for chemotherapy dosing

Clinical actions taken in response to an adverse event.

NCI CTCAE v5.0 adverse event terms for oncology toxicity grading.

CTCAE attribution codes for causality assessment of adverse events

NCI CTCAE v5.0 severity grades for adverse events.

CTCAE outcome codes for adverse event resolution status

Histological tumour grade codes based on degree of differentiation.

Presenting symptoms and clinical manifestations of cancer.

Anatomical primary site codes for malignancies, aligned with ICD-10.

Cancer stage summary codes for oncology staging

Cancer stage type codes indicating clinical, pathological or post-therapy staging

Cancer suspicion level codes for pre-diagnosis clinical assessment

Care plan categories for oncology care plans

Care team category codes for oncology multidisciplinary teams

Condition category codes for oncology diagnoses

Condition clinical status codes for oncology diagnoses

Condition severity codes for oncology diagnoses

Condition verification status codes for oncology diagnoses

Diagnostic test urgency codes for prioritising oncology investigations

Codes describing the extent of disease spread at assessment.

ECOG performance status codes for assessing patient functional ability

Episode of care status codes for oncology episodes

Episode of care type codes identifying the healthcare programme

Generic names of chemotherapy agents and oncology medications used in Kenya.

Anatomical body site codes aligned with ICD-11 topology.

Disease severity classification codes aligned with ICD-11.

Codes indicating the side of the body affected by a malignancy.

Manifestation and symptom codes

Routes by which oncology medications are administered.

Reasons for medication administration status in oncology

Codes classifying the clinical role of a medication in an oncology regimen.

Reasons for medication request status changes in oncology

Sites of distant metastatic spread.

Morphology codes for histopathological classification of cancer

Morphology method codes indicating how tissue was obtained for histopathology

Biomarker and molecular marker codes for treatment protocol selection.

ICD-10 diagnosis codes for common malignancies in Kenya.

Codes indicating certainty and method of cancer diagnosis confirmation.

Status codes for oncology encounters.

Oncology encounter type codes for classifying clinical visits

Clinical and non-clinical roles in the oncology multidisciplinary team.

Units of measure for oncology drug dosing and administration quantities.

Route of administration codes for medication prescribing and administration

Plan definition type codes for oncology regimen templates and protocols

Codes representing the outcome of a prior oncology treatment course.

Procedure codes used in oncology care plans

Scheduled imaging timepoints for RECIST 1.1 tumour response assessment.

RECIST response assessment codes for tumour response evaluation

Radiation beam or source type used in treatment delivery.

Clinical intent codes for a radiotherapy treatment course.

ICRU-defined target volume concepts for radiotherapy planning.

Technical approach codes for radiotherapy delivery.

Reason for cancer suspicion codes capturing clinical basis for suspicion

Codes indicating the origin of an oncology referral.

SHA benefit package codes for oncology interventions.

TNM Clinical M stage codes for oncology staging

TNM Clinical N stage codes for oncology staging

TNM Clinical T stage codes for oncology staging

Standard oncology chemotherapy regimen codes used in Kenya.

Codes representing the clinical intent of oncology treatment.

Codes indicating the care setting for oncology treatment delivery.

Adverse event category codes from MOH-KENYA KNHTS

Body surface area formula codes from MOH-KENYA KNHTS (BSA-FORMULA)

Codes for the type of bone marrow or haematopoietic stem cell transplant.

Codes indicating the clinical action taken in response to an adverse event.

NCI CTCAE v5.0 adverse event terms used in oncology toxicity grading.

CTCAE attribution/causality codes from MOH-KENYA KNHTS

NCI CTCAE v5.0 severity grades for adverse events.

CTCAE outcome codes from MOH-KENYA KNHTS

Histological tumour grade codes based on degree of differentiation.

Codes for presenting symptoms, signs, and clinical manifestations of cancer.

Codes for the anatomical primary site of a malignancy, aligned with ICD-10 topography.

Cancer stage summary codes from MOH-KENYA KNHTS (CANCER-STAGE-SUMMARY)

Cancer stage type codes from MOH-KENYA KNHTS (CANCER-STAGE-TYPE)

Cancer suspicion level codes from MOH-KENYA KNHTS

Care plan categories from MOH-KENYA KNHTS (CARE-PLAN-CATEGORY)

Care team category codes from MOH-KENYA KNHTS (CARE-TEAM-CATEGORY)

TNM Clinical M codes from MOH-KENYA KNHTS (CLINICAL-M)

TNM Clinical N codes from MOH-KENYA KNHTS (CLINICAL-N)

TNM Clinical T codes from MOH-KENYA KNHTS (CLINICAL-T)

Condition category codes from MOH-KENYA KNHTS

Condition clinical status codes from MOH-KENYA KNHTS

Condition severity codes from MOH-KENYA KNHTS (CONDITION-SEVERITY)

Condition verification status codes from MOH-KENYA KNHTS

Diagnostic test urgency codes from MOH-KENYA KNHTS

Codes describing the extent of disease spread at the time of assessment.

ECOG performance status codes from MOH-KENYA KNHTS

Episode of care status codes from MOH-KENYA KNHTS

Episode of care type codes from MOH-KENYA KNHTS

Generic names of chemotherapy agents and oncology medications used in Kenya.

Anatomical body site codes used in oncology diagnosis and staging, aligned with ICD-11 topology.

Severity classification codes aligned with ICD-11 severity axes.

Codes indicating the side of the body affected by the malignancy or treatment.

Manifestation/symptom codes from MOH-KENYA KNHTS (MANIFESTATION-OR-SYMPTOM)

Codes for the route by which oncology medications are administered.

Medication administration status reason codes from MOH-KENYA KNHTS

Codes classifying the clinical role of a medication within an oncology regimen.

MedicationRequest status reason codes from MOH-KENYA KNHTS

Codes for sites of distant metastatic spread.

Morphology codes from MOH-KENYA KNHTS (MORPHOLOGY-CODES)

Morphology method codes from MOH-KENYA KNHTS (MORPHOLOGY-METHOD)

Biomarker and molecular marker codes used for treatment protocol selection.

ICD-10 diagnosis codes for the most common malignancies in Kenya.

Codes indicating the certainty and method of confirmation of an oncology diagnosis.

Status codes for oncology encounters, aligned with FHIR R4 encounter-status.

Oncology encounter type codes from MOH-KENYA KNHTS (ONCOLOGY-ENCOUNTER-TYPE)

Codes for clinical and non-clinical roles within the oncology multidisciplinary team.

Units of measure for oncology drug dosing and administration quantities.

Route of administration codes from MOH-PPB KNHTS

Plan definition type codes from MOH-KENYA KNHTS (PLAN-DEFINITION-TYPE)

Codes representing the outcome of a prior oncology treatment course.

Procedure codes from MOH-KENYA KNHTS (PROCEDURE-CODE)

Codes for the scheduled imaging timepoint used in RECIST 1.1 tumour response assessment.

RECIST response assessment codes from MOH-KENYA KNHTS

Codes for the radiation beam or source type used in treatment delivery.

Codes for the clinical intent of a radiotherapy treatment course.

ICRU-defined target volume concepts used in radiotherapy planning.

Codes for the technical approach used in delivering radiotherapy.

Reason for cancer suspicion codes from MOH-KENYA KNHTS

Codes indicating the source or origin of an oncology referral.

Social Health Authority (SHA) benefit package codes for oncology interventions.

Standard oncology chemotherapy regimen codes used in Kenya.

Codes representing the clinical intent of an oncology treatment.

Codes indicating the care setting in which oncology treatment is delivered.

Identifier system for oncology diagnostic service requests (lab, imaging, pathology) within the Kenya NCCP programme.

Identifier system for oncology episodes of care within the Kenya NCCP programme.

Identifier system for chemotherapy and oncology medication requests within the Kenya NCCP programme.

Identifier system for oncology chemotherapy care plans issued within the Kenya NCCP programme.

Identifier system for oncology clinical encounters (treatment sessions, consultations, diagnostic visits) within the Kenya NCCP programme.

Identifier system for radiotherapy care plans issued within the Kenya NCCP programme.

Identifier system for oncology regimen templates (PlanDefinitions) within the Kenya NCCP programme.

Identifier system for oncology request groups (treatment session bundles) within the Kenya NCCP programme.

BSA 1.75 m² calculated by Mosteller formula (height 165 cm, weight 70 kg) pre-cycle 1

CTCAE Grade 2 nausea recorded on cycle 1 day 3 post AC chemotherapy; dose not modified

High-level clinical suspicion of cervical cancer at screening visit based on abnormal cytology and clinical finding

Placeholder care plan used as a reference target in medication and financial example instances.

Placeholder care team used as a reference target in care plan examples.

Doxorubicin 60 mg/m² IV short infusion, day 1 of cycle 1 for breast cancer (AC regimen)

Placeholder condition instance used as a reference target in example instances.

Placeholder SHA insurance coverage used as a reference target in financial examples.

Request to verify SHA coverage eligibility for AC-T chemotherapy regimen (breast cancer)

Histopathology report confirming squamous cell carcinoma of the cervix from colposcopy-directed biopsy

Urgent colposcopy and directed biopsy request for suspected cervical cancer

Placeholder diagnostic service request used as a reference target in diagnostic report examples.

ECOG performance status 1 recorded at cycle 1 pre-treatment assessment; patient ambulatory with mild symptoms

Placeholder encounter used as a reference target in example instances.

Placeholder episode of care used as a reference target in encounter examples.

Actual administration of Doxorubicin 105 mg IV (BSA 1.75 m²) on 15 Jan 2026, cycle 1

Placeholder medication administration used as a reference target in adverse event examples.

Placeholder medication request used as a reference target in medication administration examples.

Histopathology core-needle biopsy confirming invasive ductal carcinoma of the left breast

Example AC-T 21-day chemotherapy care plan for a breast cancer patient

Example diagnosis of breast cancer using ICD-11 coding

Grade 3 febrile neutropenia reported day 10 post AC cycle 1; patient hospitalised for IV antibiotics

Multidisciplinary team managing a breast cancer patient at Kenyatta National Hospital

Placeholder claim used as a reference target in claim response examples.

SHA pre-authorisation approval for 6 cycles of AC-T chemotherapy (8 sessions) for breast cancer

SHA insurance claim for Doxorubicin + Cyclophosphamide (AC) cycle 1 session 1 for breast cancer

Day-case chemotherapy session at Kenyatta National Hospital oncology unit, cycle 1 session 1

Active episode of cancer care for a breast cancer patient at Kenyatta National Hospital

Regimen template for AC-T: Doxorubicin + Cyclophosphamide → Paclitaxel, 8 × 21-day cycles

Referral of a newly diagnosed breast cancer patient from Machakos County Hospital to KNH Oncology

Groups all medication requests for AC cycle 1 session 1 for breast cancer patient

Placeholder oncology unit organisation used as a reference target in example instances.

Placeholder patient used as a reference target in example instances.

Placeholder practitioner (oncologist) used as a reference target in example instances.

Prior autologous peripheral blood stem cell transplant after melphalan conditioning for multiple myeloma

Prior concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer in 2023

Prior wide local excision (lumpectomy) of left breast for stage IIB invasive ductal carcinoma

5 years of adjuvant tamoxifen for ER+ breast cancer (2018–2023) prior to current recurrence

Baseline RECIST measurement: sum of longest diameters of 3 target lesions = 58 mm (breast cancer)

RECIST new lesion check at week 8 assessment: no new lesions identified on CT scan

RECIST non-target lesion assessment: liver lesion present/non-measurable at week 8 assessment

RECIST response assessment after 2 cycles of chemotherapy

RECIST target lesion measurement of left axillary lymph node at week 8 (after 2 AC cycles): 18 mm

Placeholder radiotherapy care plan used as a reference target in radiotherapy treatment examples.

Placeholder radiation therapist used as a reference target in radiotherapy examples.

Adjuvant 3DCRT care plan for left breast cancer post-lumpectomy: 25 fractions × 2 Gy (50 Gy total)

End-of-treatment dose summary: 50 Gy total dose, 25 fractions × 2 Gy, PTV whole breast

Standard adjuvant whole breast radiotherapy protocol: 50 Gy in 25 fractions using 3D conformal technique

Prescription for adjuvant whole breast radiotherapy following lumpectomy for left breast cancer

First fraction delivery of adjuvant left breast radiotherapy; 2 Gy delivered, cumulative dose 2 Gy

TNM staging observation T2 N1 M0 for a breast cancer patient

Placeholder RECIST target lesion observation used as a reference target in response assessment examples.

Placeholder KNH Oncology department used as a reference target in referral examples.

Placeholder oncology day unit location used as a reference target in example instances.

Placeholder Social Health Authority insurer used as a reference target in financial examples.